Room: Grand Ballroom


Poster Session A

Presenting Monday through Tuesday


Amgen, Inc.

A1.      Integrated Cell Culture Continuous Manufacturing (CM) and Real-Time Process Analytical Technology (PAT) Implementation for Biologics Production; Presented by Sherry Y.

BioGenes GmbH

A2.      Frequent Challenges of Host Cell Protein ELISA Projects; Presented by Yvonne H.

Bruker Daltonik

A3.      Routine Analysis of Host Cell Proteins in Antibody Preparations Using PASEF LC-MS/MS; Presented by Dirk W.

Caprion Biosciences, Inc.

A4.      Mass Spectrometry Platforms for High Coverage Process-Specific HCP Identification and Quantitation; Presented by Michael S.

Celgene Corporation

A5.      Implementation of an Integrated E2E Bioprocess Development Workflow Platform at Celgene; Presented by James D.

ChromaTan Corporation

A6.      Continuous Countercurrent Tangential Chromatography (CCTC) for Capture and Polishing of Monoclonal Antibodies; Presented by Oleg S.

PROAnalytics LLC

A7.      RX Series; Presented by Justin L.

ETH Zurich

A8.      Twin-Column Counter-Current Chromatography for Purification of Biologics; Presented by Thomas M.

Fluence Analytics

A9.      Static Light Scattering Signatures Used to Identify Stability During Formulation Development; Presented by Stephanie M.

Genedata, Inc.

A10.    High-Throughput Screening for Best Manufacturing of Cell Lines Using Scale-Down Models; Presented by Andrew L.

Genedata, Inc.

A11.    Strategies for Monitoring Host Cell Proteins in Biopharmaceutical Development, Production and Quality Control; Presented by John M.

GenScript USA, Inc.

A12.    Biologics IND Application: CMC Platform by GenScript; Presented by Bowu L.

Halo Labs

A13.    HORIZON - High Throughput Low Volume Subvisible Particle Analysis; Presented by Bernardo C.

Hebrew Univeristy Jerusalem

A14.    Biuret, the AtzE Substrate, Does Not Increase Further Cell Density and Biomass Production in Rhizobium Leguminosarum Bacterial Culture; Presented by Ilana H.

HTL Biosolutions, Inc.

A15.    Higher Order Structural Characterization of A Monoclonal Antibody and Its Aggregates During Formulation Development by Using Raman Spectroscopy; Presented by Tiansheng L.

KBIO Osong Medical Innovation Foundation

A16.    Strategies for Improving Surfactant Screening by Using Particle Analysis; Presented by Minsik K.

Lonza AG

A17.    Platform Approach for Drug Product Simulated Administration Compatibility for Clinical Administration: Concept Study Design and Challenges for Biologics; Presented by Stephanie L.

Lonza Biologics

A18.    Use of In Silico and Expression Tools to Support Lead Selection; Presented by Yvette S.

MaxCyte, Inc.

A19.    De-Risking Biotherapeutic Development: Maximizing Transient Productivity and Improved Data Relevance Using a Fully Scalable Cell Engineering Technology; Presented by Joan H.

Merck Biodevelopment

A20.    Accelerated Formulation Strategy for Monoclonal Antibody; Presented by Alice L.

NanoTemper Technologies

A21.    Improving Biologics Workflow-Detailed Characterization of Quality, Binding and Stability of mAbs; Presented by Peter F.

National Research Council Canada

A22.    CHO-BRI Inducible Antibody Fed-Batch Production Platform: Impact of Process Parameters on Production Performance; Presented by Phuong Lan P.


A23.    Selection of Suitable Flow Meter Technology for Bioprocess Applications; Presented by Mark M.

Polyplus-Transfection SA

A24.    Advanced CHO Cell Expression System for Increased Transient Protein Production; Presented by Geraldine G.

Protein Dynamic Solutions LLC

A25.    A High Throughput-Developability and Comparability Assessment (HT-DCA) Platform Providing a Transformative Solution for the Study of Proteins; Presented by Belinda P.

RedShift BioAnalytics, Inc.

A26.    Repeatability, Concentration Linearity and High Order Structure Analysis of an IgG1 Sample by Microfluidic Modulation Spectroscopy (MMS); Presented by Jeffrey Z.

Rockland Immunochemicals, Inc.

A27.    Evaluation of Novel High Coverage Generic CHO-HCP Reagents; Presented by Anthony F.


A28.    Characterization of an Intensified Perfusion Platform at the Cellular Level; Presented by Kristina W.

Teva Pharmaceuticals USA, Inc.

A29.    Evaluation of Interactive Effects of Silicone and Tungsten on Protein Quality Attributes; Presented by Naveen R.

Thermo Fisher Scientific

A30.    Strategies for High-Titer Protein Expression Using the ExpiCHO and Expi293 Transient Expression Systems; Presented by Chao Yan L.

Thermo Fisher Scientific

A31.    ExpiSf: A Chemically Defined Baculovirus-Based Expression System for Enhanced Protein Production in SF9 Cells; Presented by Kenneth T.

U.S. Food and Drug Administration

A32.    Utilizing Minimum-Volume Analytical Techniques to Assay the Structural Heterogeneity of IgG1; Presented by Phillip A.

U.S. Food and Drug Administration

A33.    Developing Models for Validation of Virus Removal by Continuous Chromatography; Presented by Meng-Jung C.

Unchained Labs

A34.    Meet Our Uncle: A Multimodal Instrument for Characterizing Protein Stability; Presented by Lisa A.

University of Connecticut

A35.    Detection of Tertiary Structural Changes in Solid State Proteins Using Raman Spectroscopy: Implications for Protein Formulation and Stability; Presented by Lauren F.

Waters Corporation

A36.    Identification and Monitoring of Host Cell Proteins in Biopharmaceuticals by a LC/MS Approach in Support of Bioprocess Development; Presented by Weibin C.



Poster Session B

Presenting Wednesday through Thursday


908 Devices, Inc.

B1.      An Integrated Benchtop Analyzer for the Rapid Analysis of Cell Growth Media; Presented by Glenn H.

Abbott Laboratories

B2.      Single-Step Purification of a His-Tagged Recombinant Fab; Presented by Wan-Ching L.

Amgen, Inc.

B3.      Novel High Capacity Protein A Membrane Capture Step for Fc-Based Modalities; Presented by Caleb C.

Bristol-Myers Squibb

B4.      Viral Filtration DoE Screening Study for a Biologic Using a Model Bacteriophage; Presented by Zhen T.

Dankook University

B5.      Porous 3D Printed Scaffolds with Stem Cell for Guided Bone Regeneration; Presented by Chung Hun O.

Fluid Imaging Technologies, Inc.

B6.      FlowCam® Nano Provides Counts, Sizes and Images of Nano-and Microparticles: Application to a Therapeutic Protein Pumping Study; Presented by Dave H.

Genedata, Inc.

B7.      An Automated Approach for Comprehensive Characterization and Quantification of Low-Abundance Sequence Variants in a Standard Monoclonal Antibody; Presented by David B.

Genedata, Inc.

B8.      End-to-End Workflow Platform for Integrated Biopharmaceutical Development; Presented by Bernie E.

Genedata, Inc.

B9.      A Platform Approach to Decrease Developability and Manufacturability Risks of Biologics Molecules; Presented by Amanda F.

Genedata, Inc.

B10.    Application of Next Generation Sequencing for Biosafety Assessment of Biologics; Presented by Marcell V.

Genentech, Inc.

B11.    Advances in Multi-Product Use Resins; Presented by Yolanda N.

GenScript USA, Inc.

B12.    SMAB (Single-Domain Antibody Fused to Monoclonal Antibody) Bispecifics: Achieve Blockbuster Antibody Standards in Next Generation Therapeutics; Presented by Sasidhar M.

Green Cross LabCell

B13.    Process Development for Large-Scale Ex-Vivo Expansion of Allogeneic Natural Killer Cells in Stirred-Tank Bioreactor; Presented by Sanghyun L.

HocusLocus, Inc.

B14.    Using RNAi and Magnetically Activated Cell Sorting for Cell Line Selection; Presented by Edward E.

ImmunoGen, Inc.

B15.    Comprehensive Manipulation of Glycosylation Profiles Across Development Scales; Presented by Kristina L.

Janssen Research and Development

B16.    Use of the Cyto-Mine® for Rapid Generation of High-Producing Clonal Cell Lines; Presented by Angela T.

Lawrence Livermore National Laboratory

B17.    Development of a Biosorption Process for Recovery of Precious Metals; Presented by Yongqin J.

Lindy Biosciences

B18.    Microglassification™: A Novel Dehydration Process Enabling Low Viscosity, Highly Concentrated Injectable Suspensions of Biologics; Presented by Michael D.


B19.    Development of Robust Processes for Large Scale Antibody-Drug Conjugation; Presented by Bethanne D.

Magenta Therapeutics

B20.    Improvement in Thermal Stability of Antibodies and ADCs with Rationally Chosen Formulations; Presented by Junia D.

MaxCyte, Inc.

B21.    Bolstering Therapeutic Efficacy and Speed to Clinic Using Non-Viral T-Cell Engineering; Presented by Krista S.

Merck & Co., Inc.

B22.    Epigenome Characterization of CHO Cells; Presented by Amit K.

MockV Solutions LLC

B23.    Predicting MVM Clearance by Nanofiltration and Anion Exchange Chromatography Using a Non-Infectious “Mock Virus Particle"; Presented by David C.

Novartis Pharmaceuticals Corporation

B24.    Novel Application of AMBR 250 for CAR-T Cell Therapy Bioprocess Automation and Future Commercialization; Presented by Vienna L.


B25.    Characterization of NIST mAb with Microfluidic CE-SDS Using the Protein Clear HRTM Assay; Presented by James W.


B26.    Flexible Clean Room Designs; Presented by James L.

Pfizer, Inc.

B27.    AMBR250 Modular Demo Summary with Complex Cell Culture Processes; Presented by Inci O.

Polyplus-Transfection SA

B28.    Addressing Large-Scale Manufacturing of Clinical Grade Viral Vectors Using an Optimized PEI-Based Transfection Process; Presented by Julien D.

ProZyme, Inc.

B29.    High Throughput CE-Based N-Glycan Analysis for Clone Screening in Biotherapeutic Protein Production; Presented by Justin H.


B30.    The Influence of Complexing Time and Transfection Reagents on AAV Production; Presented by Robert S.


B31.    Effect of Transfection Enhancers on AAV Vector Production; Presented by Miguel V.

Roche Pharma Research and Early Development

B32.    Downstream Processing of a Monoclonal Bispecific Antibody - A Case Study; Presented by Stefan F.

Rockland Immunochemicals, Inc.

B33.    Robust Methods for Anti-Oligonucleotide Antibody Generation; Presented by Daniel K.


B34.    Integration of an Automatic Sampling Device with an Intensified Perfusion Platform; Presented by Jared F.

St. Jude Children's Research Hospital

B35.    Lentiviral Vector Production from a Stable Packaging Cell Line Using an iCELLis® Bioreactor; Presented by Alicia P.

Thermo Fisher Scientific

B36.    Mixing Operations for 50 L to 2000 L Single-Use Mixer: Liquid-Liquid Mixing Characterization and Slurry Suspensions; Presented by Jordan C.

Thermo Fisher Scientific

B37.    Monoclonal Antibody Aggregate Removal Using POROS Hydrophobic Interaction Chromatography (HIC) Resins in Bind-Elute Mode; Presented by Stephen H.

U.S. Food and Drug Administration

B38.    Integrating High Throughput Analytics with Early-Stage Cell Line Development: A Comprehensive Quality Attribute Characterization of CHO Clone Candidates Expressing a Model IgG1 Antibody; Presented by Casey K.

U.S. Food and Drug Administration

B39.    Growth Parameters and Media Dependent Effects on Antibody Product Quality: Glycosylation and Aglycosylation; Presented by David P.

UBE Industries, Ltd.

B40.    Novel Bioreactor System for Continuous IgG Production; Presented by Masahiko H.

University of Connecticut

B41.    Freeze-Drying of Highly Concentrated Proteins: Effect of Formulation and Processing on Phase Composition, Porous Structure and Reconstitution Time; Presented by Shreya K.

University of Manchester

B42.    Liquid-Liquid Equilibrium of a Monoclonal Antibody in Terms of Protein-Protein Interactions; Presented by Nicole S.

University of Natural Resources and Life Sciences (BOKU)

B43.    Critical Quality Attributes in Recombinant IgM Production and How They Are Influenced by External Process Conditions; Presented by Julia H.

University of Natural Resources and Life Sciences (BOKU)

B44.    Automated, High-Throughput Content Analysis in Process Development; Presented by Martin V.

Waters Corporation

B45.    Improving Glycan Profiling in Process Development Using Spectral Library; Presented by Ximo Z.

SCIEX Separations

B46.    Repeatability of the C100HT Biologics Analyzer, a High Throughput Glycan Screening Platform; Presented by Mark L.